LivaNova LIVN Cardiopulmonary — 3T litigation provision
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by LivaNova in its filing.
Tagged under the XBRL concept us-gaap:LossContingencyAccrualProvision.
The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about LivaNova's cardiopulmonary — 3t litigation provision.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is LivaNova's cardiopulmonary — 3t litigation provision?
- LivaNova (LIVN) reported cardiopulmonary — 3t litigation provision of $15K in Q1 2026.
- How has LivaNova's cardiopulmonary — 3t litigation provision changed year-over-year?
- LivaNova's cardiopulmonary — 3t litigation provision decreased by 97.9% year-over-year, from $706K to $15K.
- What is the long-term trend for LivaNova's cardiopulmonary — 3t litigation provision?
- Over 4 years (2021 to 2025), LivaNova's cardiopulmonary — 3t litigation provision has grown at a -41.8% compound annual growth rate (CAGR), from $38.1M to $4.38M.
- What does cardiopulmonary — 3t litigation provision mean?
- Represents the estimated financial liability accrued for legal matters specifically related to the 3T product line within the cardiopulmonary segment. It highlights potential financial risks and the impact of legal contingencies on segment profitability.